Ultrafast magnetic resonance imaging protocols in stroke
http://www.100md.com
《神经病学神经外科学杂志》
Correspondence to:
Professor E B Ringelstein
Klinik und Poliklinik für Neurologie, Universit?tsklinikum Münster, Albert-Schweitzer-Str 33, 48149 Münster, Germany D-48129; ringels@uni-muenster.de
Profound changes in the protocols for the management of acute stroke patients irrespective of whether ischaemic or haemorrhagic in origin
Keywords: stroke
Although the approval of recombinant tissue plasminogen activator (rtPA) for the treatment of acute ischaemic stroke has been based on the primary imaging technique of conventional cerebral computerised tomography (CT),1 newer and more refined magnetic resonance (MR) techniques are unrelentlessly extending into this particular field of emergency medicine, stimulated by the important hope that these new techniques could help to prolong the therapeutic time window beyond the 3 hour limit in selected patients. Several recent papers have clearly demonstrated that the mismatch concept,2 though leading to diagnostic pitfalls in a small number of cases as well, seems to be helpful in selecting patients for "late" fibrinolysis. It has been shown that the rapidity with which the inevitable core infarction augments into the tissue at risk ( = penumbra) does not only depend on external parameters like perfusion pressure, blood glucose level, body temperature, or oxygen saturation (to mention only a few), but is strongly influenced by individual, predefined anatomical features of the cerebral vasculature like the configuration of the circle of Willis and the collateralising potential of the leptomeningeal anastomoses at the cortical level.3
The indication for systemic fibrinolysis in acute stroke is not dependent on the angiological proof of an intracranial arterial occlusion. The conflict between the desire to base fibrinolysis on pathophysiologically relevant knowledge, and the urge of the therapeutic time window with an exponentially decreasing benefit from lysis over time led to a decision in favour of the time requirements. It could be argued, however, that patients without a visible arterial occlusion would not need fibrinolysis at all, and should not be exposed to its intrinsic risks.
With this in mind the idea to subject nearly every acute stroke patient to an ultrafast MR imaging protocol including T1, T2, fluid attenuated inversion recovery (FLAIR), and diffusion weighted imaging (DWI) sequences in addition to three dimensional time-of-flight MR to visualise the major cerebral arteries appears very attractive even though this technology and the corresponding expertise is not available yet over 24 hours in most places. Until now, the most convincing argument against this refined diagnostic work-up of the acute stroke patient was the limitation of time. This is no longer valid, however, and postprocessing efforts lasted only 7 minutes, during which time the patient was returned to the ward. With this ultra fast MRI technique, even the handling of restless and uncooperative patients did not seem to be a problem anymore—another important argument often posed against MR imaging in the very acute phase of stroke.
A technique like the one described by U-King-Im et al (this issue, pp 1002–5), supplemented by an additional haemosiderin-sensitive gradient echo sequence for the detection of previous haemorrhages might initiate profound changes in the protocols for the management of acute stroke patients irrespective whether ischaemic or haemorrhagic in origin. Realistic hopes are that: (1) ideal candidates for fibrinolysis could be pinpointed; (2) the time window for fibrinolysis could be prolonged on an individual basis; (3) the risk of intracerebral haemorrhage could be reduced by excluding patients without a visible arterial lesion; and (4) patients with multiple haemosiderin remnants indicating previous brain haemorrhages could be excluded as well, because of their excessive bleeding risk. In patients with peracute brain haemorrhage, recombinant activated Factor VII could be applied to stop the growth of the haematoma.4 If this works, only two major obstacles still seem to be present: the patients’ cardiac pacemakers and defibrillators, and the costs.
REFERENCES
NINDS. (National Institute of Neurological Disorders and Stroke rt-PA) Stroke Study-Group. Tissue Plasminogen Activator for Acute Ischaemic Stroke. In: N Engl J Med 1995;333:1581–7.
R?ther J, Schellinger PD, Gass A, for the Kompetenznetzwerk Schlaganfall Study Group, et al. Effect of Intravenous Thrombloysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours. Stroke 2002;33:2438–45.
Ringelstein EB, Biniek R, Weiller C, et al. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992;42:289–98.
Mayer SA, Brun NC, Broderick J, et al. Europe/AustralAsia NovoSeven ICH Trial Investigators. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005;36:74–9.(E B Ringelstein)
Professor E B Ringelstein
Klinik und Poliklinik für Neurologie, Universit?tsklinikum Münster, Albert-Schweitzer-Str 33, 48149 Münster, Germany D-48129; ringels@uni-muenster.de
Profound changes in the protocols for the management of acute stroke patients irrespective of whether ischaemic or haemorrhagic in origin
Keywords: stroke
Although the approval of recombinant tissue plasminogen activator (rtPA) for the treatment of acute ischaemic stroke has been based on the primary imaging technique of conventional cerebral computerised tomography (CT),1 newer and more refined magnetic resonance (MR) techniques are unrelentlessly extending into this particular field of emergency medicine, stimulated by the important hope that these new techniques could help to prolong the therapeutic time window beyond the 3 hour limit in selected patients. Several recent papers have clearly demonstrated that the mismatch concept,2 though leading to diagnostic pitfalls in a small number of cases as well, seems to be helpful in selecting patients for "late" fibrinolysis. It has been shown that the rapidity with which the inevitable core infarction augments into the tissue at risk ( = penumbra) does not only depend on external parameters like perfusion pressure, blood glucose level, body temperature, or oxygen saturation (to mention only a few), but is strongly influenced by individual, predefined anatomical features of the cerebral vasculature like the configuration of the circle of Willis and the collateralising potential of the leptomeningeal anastomoses at the cortical level.3
The indication for systemic fibrinolysis in acute stroke is not dependent on the angiological proof of an intracranial arterial occlusion. The conflict between the desire to base fibrinolysis on pathophysiologically relevant knowledge, and the urge of the therapeutic time window with an exponentially decreasing benefit from lysis over time led to a decision in favour of the time requirements. It could be argued, however, that patients without a visible arterial occlusion would not need fibrinolysis at all, and should not be exposed to its intrinsic risks.
With this in mind the idea to subject nearly every acute stroke patient to an ultrafast MR imaging protocol including T1, T2, fluid attenuated inversion recovery (FLAIR), and diffusion weighted imaging (DWI) sequences in addition to three dimensional time-of-flight MR to visualise the major cerebral arteries appears very attractive even though this technology and the corresponding expertise is not available yet over 24 hours in most places. Until now, the most convincing argument against this refined diagnostic work-up of the acute stroke patient was the limitation of time. This is no longer valid, however, and postprocessing efforts lasted only 7 minutes, during which time the patient was returned to the ward. With this ultra fast MRI technique, even the handling of restless and uncooperative patients did not seem to be a problem anymore—another important argument often posed against MR imaging in the very acute phase of stroke.
A technique like the one described by U-King-Im et al (this issue, pp 1002–5), supplemented by an additional haemosiderin-sensitive gradient echo sequence for the detection of previous haemorrhages might initiate profound changes in the protocols for the management of acute stroke patients irrespective whether ischaemic or haemorrhagic in origin. Realistic hopes are that: (1) ideal candidates for fibrinolysis could be pinpointed; (2) the time window for fibrinolysis could be prolonged on an individual basis; (3) the risk of intracerebral haemorrhage could be reduced by excluding patients without a visible arterial lesion; and (4) patients with multiple haemosiderin remnants indicating previous brain haemorrhages could be excluded as well, because of their excessive bleeding risk. In patients with peracute brain haemorrhage, recombinant activated Factor VII could be applied to stop the growth of the haematoma.4 If this works, only two major obstacles still seem to be present: the patients’ cardiac pacemakers and defibrillators, and the costs.
REFERENCES
NINDS. (National Institute of Neurological Disorders and Stroke rt-PA) Stroke Study-Group. Tissue Plasminogen Activator for Acute Ischaemic Stroke. In: N Engl J Med 1995;333:1581–7.
R?ther J, Schellinger PD, Gass A, for the Kompetenznetzwerk Schlaganfall Study Group, et al. Effect of Intravenous Thrombloysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours. Stroke 2002;33:2438–45.
Ringelstein EB, Biniek R, Weiller C, et al. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992;42:289–98.
Mayer SA, Brun NC, Broderick J, et al. Europe/AustralAsia NovoSeven ICH Trial Investigators. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005;36:74–9.(E B Ringelstein)